Comparative Pharmacology
Head-to-head clinical analysis: EQUAGESIC versus ETHCHLORVYNOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUAGESIC versus ETHCHLORVYNOL.
EQUAGESIC vs ETHCHLORVYNOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Equagesic is a combination of aspirin and meprobamate. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis. Meprobamate potentiates GABA-A receptor activity, producing anxiolytic and sedative effects.
Ethchlorvynol is a sedative-hypnotic with central nervous system depressant effects. Its exact mechanism is unknown, but it may potentiate GABA activity or depress neuronal excitability.
Adults: 1 tablet (200 mg meprobamate, 25 mg ethoheptazine citrate, 325 mg aspirin) orally 3 or 4 times daily.
500 mg to 1 g orally at bedtime as needed for insomnia.
None Documented
None Documented
Meprobamate: 10-12 hours in healthy adults, prolonged in liver disease; Aspirin: low doses 2-3 hours, anti-inflammatory doses 15-30 hours (saturable elimination).
Clinical Note
moderateEthchlorvynol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate."
Clinical Note
moderateEthchlorvynol + Clemastine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine."
Clinical Note
moderateEthchlorvynol + Venlafaxine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine."
Clinical Note
moderate10-25 minutes (initial rapid distribution phase); terminal elimination half-life approximately 4-6 hours in adults (prolonged in liver disease due to reduced clearance).
Meprobamate: renal (10% as unchanged drug, 80-90% as hydroxylated metabolites); Aspirin: renal (dose-dependent, 50-80% as salicyluric acid, 10% as unchanged salicylate at acidic pH).
Renal: <1% unchanged; Hepatic metabolism to inactive conjugates; Fecal: minimal. Approximately 90% of a dose is excreted in urine as glucuronide conjugates within 24 hours.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic
Ethchlorvynol + Nefazodone
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone."